INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Indivior (INDV) agreed to a tax-free, all-stock merger with Supernus (SUPN). Indivior shareholders will own about 56.5% and Supernus 43.5%. The combined CNS-focused company is expected to close in Q4 2026 and trade on Nasdaq under SUPN. Pro forma: ~$2.2B revenue, $888M adjusted EBITDA, $125M synergies. Indivior Q2 2026: adj. EPS $1.15, revenue $343M.
How this was made
The 30-second read
Why it matters
The article combines two catalysts: (1) a definitive M&A agreement with ownership split, synergy and revenue/EBITDA pro forma targets, and (2) Indivior’s Q2 earnings beat with strong Sublocade growth. Despite the earnings outperformance, INDV shares fell 6.6% on the merger announcement, suggesting investors are prioritizing deal risk and valuation/dilution concerns over near-term operating momentum.
Market read
Traders can act on fresh deal terms and the immediate post-announcement reaction, while monitoring approval timelines and how synergy targets affect valuation.
What to watch
Deal execution risk (integration, regulatory approvals) and how cost synergies ($125M) translate into margin and cash flow are not quantified here, leaving room for repricing.
Background
Indivior (INDV) and Supernus (SUPN) announced a definitive, tax-free all-stock merger of equals, expected to close in Q4 2026, alongside Indivior’s Q2 2026 earnings.
Ticker impact
Indivior announced a definitive, tax-free all-stock merger with Supernus and reported Q2 results, but its shares fell 6.6% on the news.
Choppy to downside-biased around deal headlines and approval risk, with support from the Q2 beat and Sublocade momentum.
The article pairs a definitive M&A agreement and deal terms with a same-article Q2 beat, yet explicitly notes INDV shares declined 6.6% after the merger announcement, implying investors are weighing dilution/uncertainty more than the earnings upside.
Supernus is the merger counterparty in a definitive all-stock deal with Indivior, with the combined company expected to trade on Nasdaq under SUPN.
Likely volatile, with direction depending on how investors price the 43.5% ownership split and deal approval odds.
The text provides deal structure and expected close timing but does not give SUPN-specific earnings details; the main actionable driver for SUPN is the merger announcement itself.
Market effects
Signals continued consolidation in CNS/addiction biopharma, potentially reshaping competitive positioning around marketed products like Sublocade.
US-listed biotech M&A sentiment may influence peer valuations on deal-spread and approval-risk expectations.
Could affect global CNS investment appetite by combining addiction leadership with broader CNS pipeline capabilities.
Counterpoint
The immediate INDV drop may be an overreaction to merger uncertainty, while the Q2 beat and Sublocade growth could reassert support once deal details are digested.
Key entities
- companyIndivior Pharmaceuticals
Announced definitive all-stock merger with Supernus and reported Q2 2026 results; shares declined 6.6% on the merger news.
- companySupernus Pharmaceuticals
Counterparty in the definitive all-stock merger; combined company expected to trade on Nasdaq under SUPN.
- productSublocade
Indivior’s marketed addiction medicine driving Q2 revenue growth, including record new patient starts.
